Adipotide (FTPP)

Preclinical only Weight Loss & Metabolism 2 sources

Adipotide, also known as FTPP (Fat Targeted Proapoptotic Peptide), is an experimental peptidomimetic designed to induce weight loss by targeting and destroying the blood vessels that supply white adipose (fat) tissue. Research in animal models, including non-human primates, has shown it can cause rapid weight loss and improve insulin resistance by triggering apoptosis in fat-supplying endothelial cells.

01Dosing reference

Amount

250-500 mcg/day (Note: Extrapolated from animal models)

Frequency

Daily

Cycle

4 weeks on, followed by a recovery period

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Targeting Prohibitin

Adipotide binds specifically to prohibitin, a protein uniquely expressed on the surface of endothelial cells in the blood vessels supplying white adipose tissue.

Inducing Apoptosis

Once bound, the peptide disrupts the mitochondrial membrane of these endothelial cells, triggering apoptosis (programmed cell death).

Fat Tissue Resorption

The destruction of these targeted blood vessels cuts off the blood supply to the fat cells, causing them to die and be reabsorbed by the body, leading to rapid fat loss.

03Human evidence

Lack of human clinical trials for weight loss

Currently, there are no published human clinical trials evaluating Adipotide specifically for weight loss or obesity, limiting its evidence base entirely to animal models.

04Preclinical evidence

Significant weight loss in non-human primates

In a study on obese rhesus macaques, Adipotide treatment resulted in an 11% decrease in body weight and a 39% decrease in fat mass over four weeks.

Improvement in metabolic markers

Rodent and monkey studies demonstrated that Adipotide rapidly improved insulin resistance and glucose tolerance alongside the reduction in white adipose tissue.

05What is known vs. unknown

Reasonably established

Adipotide targets the vasculature of white fat tissue rather than acting on the central nervous system to suppress appetite.
It has demonstrated rapid and significant fat loss in obese non-human primates.
The peptide works by inducing apoptosis in the endothelial cells that supply blood to fat cells.
Research indicates potential improvements in insulin sensitivity and metabolic health in animal models.

Unknowns & limits

The long-term safety and potential side effects in humans are completely unknown due to a lack of clinical trials.
There are concerns about potential kidney toxicity, as mild, reversible renal lesions were observed in monkey studies.
It is unclear if the body would develop resistance or compensatory mechanisms to new blood vessel formation (angiogenesis) over time.

06Safety & regulatory context

Regulatory statusAdipotide is an experimental research chemical and is not approved by the FDA or any regulatory body for human use. Because it has not undergone clinical trials for obesity in humans, its safety profile is largely unknown. In animal studies, the most notable side effect was predictable, reversible kidney toxicity (renal lesions and changes in kidney function markers). Due to its mechanism of inducing cell death in blood vessels, there are theoretical risks of off-target vascular damage. It is strictly for laboratory research purposes.

07Compared with Semaglutide (GLP-1)

Adipotide (FTPP) vs. Semaglutide (GLP-1)

Key difference

Semaglutide promotes weight loss primarily by suppressing appetite and delaying gastric emptying via central nervous system and gut receptors, whereas Adipotide directly destroys the blood supply to fat cells without affecting appetite.

When researchers discuss each

Semaglutide is discussed as an FDA-approved, incretin-based therapy for obesity and diabetes, while Adipotide is discussed as an experimental, targeted vascular approach to fat reduction.

08Glossary

Apoptosis

A process of programmed cell death that occurs in multicellular organisms, used by the body to eliminate unwanted or damaged cells.

Endothelial cells

Cells that line the interior surface of blood vessels and lymphatic vessels.

Prohibitin

A protein that, in the context of Adipotide, is found on the surface of blood vessels specifically supplying white fat tissue, acting as the target receptor.

Peptidomimetic

A small protein-like chain designed to mimic a peptide, often modified to be more stable or effective in the body.

09Knowledge check

Q1What is the primary mechanism by which Adipotide (FTPP) induces weight loss in animal models?

Q2What was the most notable side effect observed in non-human primate studies of Adipotide?

Q3Which statement best describes the current level of clinical evidence supporting Adipotide for use in human obesity?

Q4Which description correctly contrasts Adipotide's approach with semaglutide, according to the dossier?

Q5Which safety or regulatory statement about Adipotide is accurate based on the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.